Vaccine reduces risk of melanoma recurrence, death by 42%: What to know

Receiving a personalized mRNA-based cancer vaccine alongside immunotherapy lowered the risk of recurrence or death by 42% versus immunotherapy alone in a phase 3 clinical trial of patients with surgically resected stage 2B to 4 melanoma. The vaccine, called intismeran autogene and jointly developed by Merck and Moderna, was tested in combination with Merck’s immunotherapy […] The post Vaccine reduces risk of melanoma recurrence, death by 42%: What to know appeared first on Becker's H...